Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer

Cioffi, Michèle; D’Alterio, Crescenzo; Camerlingo, Rosa; Tirino, Virginia; Consales, Claudia; Riccio, Anna; Ieranò, Caterina; Cecere, Sabrina Chiara; Losito, Nunzia Simona; Greggi, Stefano; Pignata, Sandro; Pirozzi, Giuseppe; Scala, Stefania

doi:10.1038/srep10357

Cited by 95 publications

(83 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well described that low O 2 tension develops in tumors in vivo [64, 65] and promotes a CSC phenotype [66]. Our study revealed that selected pRCC cell lines exposed to hypoxia in vitro increased the expression of stem-related TFs ( oct-4 and sox2 ).…”

Section: Discussionsupporting

confidence: 61%

Functional significance of CD105-positive cells in papillary renal cell carcinoma

Matak

Brodaczewska²,

Szczylik³

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundCD105 was postulated as a renal cell carcinoma (RCC) stem cell marker, and CD133 as a putative RCC progenitor. Hypoxia, a natural microenvironment that prevails in tumors, was also incorporated into the study, especially in terms of the promotion of hypothetical stem-like cell properties.MethodsWithin this study, we verify the existence of CD105+ and CD133+ populations in selected papillary subtype RCC (pRCC) cell lines. Both populations were analyzed for correlation with stem-like cell properties, such as stemness gene expression, and sphere and colony formation. For the preliminary analysis, several RCC cell lines were chosen (786-O, SMKT-R2, Caki-2, 796-P, ACHN, RCC6) and the control was human kidney cancer stem cells (HKCSC) and renal cells of embryonic origin (ASE-5063). Four cell lines were chosen for further investigation: Caki-2 (one of the highest numbers of CD105+ cells; primary origin), ACHN (a low number of CD105+ cells; metastatic origin), HKCSC (putative positive control), and ASE-5063 (additional control).ResultsIn 769-P and RCC6, we could not detect a CD105+ population. Hypoxia variously affects pRCC cell growth, and mainly diminishes the stem-like properties of cells. Furthermore, we could not observe the correlation of CD105 and/or CD133 expression with the enhancement of stem-like properties.ConclusionsBased on this analysis, CD105/CD133 cannot be validated as cancer stem cell markers of pRCC cell lines.

show abstract

Section: Discussionsupporting

confidence: 61%

Functional significance of CD105-positive cells in papillary renal cell carcinoma

Matak

Brodaczewska²,

Szczylik³

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…CD133 is a transmembrane glycoprotein with a unique structure of five transmembrane domains and two large extracellular glycosylation chains, expressed in both hematopoietic and neural stem cells (58). In several studies of HCC, the HSC surface marker CD133 was used to isolate LCSCs (47,54).…”

Section: Lcsc Surface Markers and Targeted Therapiesmentioning

confidence: 99%

Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC (Review)

Qiu

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Liver cancer stem cells (LCSCs) have important roles in the occurrence, development, recurrence, therapy resistance and metastasis of hepatocellular carcinoma (HCC). Therefore, intensive studies are undergoing to identify the mechanisms by which LCSCs contribute to HCC invasion and metastasis, and to design more efficient treatments for this disease. With continuous efforts in LCSC research over the years, therapies targeting LCSCs are thought to have great potential for the clinical treatment and prognosis of liver cancer. Novel LCSC surface markers are continuously discovered and several have been used in targeted therapies to reduce HCC recurrence, metastasis, and drug resistance following tumor resection. The present review describes the surface markers characterizing LCSCs and the recent progress in therapies targeting these markers, including antibodies and polypeptides.

show abstract

“…The expression of CD133 and CXCR4 on CSCs has been evaluated in ovarian cancer cell lines [39]. Several ovarian cancer cell lines, such as OVCAR-3, -4, and -5 and colon cancer cells, SW620 and HCT-116 express both markers.…”

Section: Heterogeneity Of Tumor Cells Before Treatmentmentioning

confidence: 99%

“…Crosstalk between intracellular signaling pathways 7 Chronopharmacology + OVCAR-5 cells, and these cells were determined to be resistant to cisplatin in transplanted nude mice. Moreover, primary ovarian cancer cells have been shown to overexpress the ATP-binding cassette (ABC) sub-family G member (ABCG) 2 drug transporter protein, CXCR4 and CD133, and have been shown to have CSCs properties, including chemoresistance and tumor development [39].…”

Section: Heterogeneity Of Tumor Cells Before Treatmentmentioning

confidence: 99%

Mechanisms of tumor cell resistance to the current targeted-therapy agents

et al. 2016

View full text Add to dashboard Cite

Resistance to chemotherapy agents is a major challenge infront of cancer patient treatment and researchers. It is known that several factors, such as multidrug resistance proteins and ATP-binding cassette families, are cell membrane transporters that can efflux several substrates such as chemotherapy agents from the cell cytoplasm. To reduce the adverse effects of chemotherapy agents, various targeted-based cancer therapy (TBCT) agents have been developed. TBCT has revolutionized cancer treatment, and several agents have shown more specific effects on tumor cells than chemotherapies. Small molecule inhibitors and monoclonal antibodies are specific agents that mostly target tumor cells but have low side effects on normal cells. Although these agents have been very useful for cancer treatment, however, the presence of natural and acquired resistance has blunted the advantages of targeted therapies. Therefore, development of new options might be necessary. A better understanding of tumor cell resistance mechanisms to current treatment agents may provide an appropriate platform for developing and improving new treatment modalities. Therefore, in this review, different mechanisms of tumor cell resistance to chemotherapy drugs and current targeted therapies have been described.

show abstract

Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer

Cited by 95 publications

References 42 publications

Functional significance of CD105-positive cells in papillary renal cell carcinoma

Functional significance of CD105-positive cells in papillary renal cell carcinoma

Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC (Review)

Mechanisms of tumor cell resistance to the current targeted-therapy agents

Contact Info

Product

Resources

About